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Abstract
Background: We intended to evaluate diagnostic utility of a targeted gene sequencing by using next generation
sequencing (NGS) panel in patients with intractable early-onset epilepsy (EOE) and find the efficient analytical step
for increasing the diagnosis rate.
Methods: We assessed 74 patients with EOE whose seizures started before 3 years of age using a customized NGS
panel that included 172 genes. Single nucleotide variants (SNVs) and exonic and chromosomal copy number variations
(CNVs) were intensively examined with our customized pipeline and crosschecked with commercial or pre-built
software. Variants were filtered and prioritized by in-depth clinical review, and finally classified according to the
American College of Medical Genetics and Genomics guidelines. Each case was further discussed in a monthly
consensus meeting that included the participation of all laboratory personnel, bioinformaticians, geneticists, and
clinicians.
Results: The NGS panel identified 28 patients (37.8%) with genetic abnormalities; 25 patients had pathogenic or likely
pathogenic SNVs in 17 genes including SXTBP1 (n = 3), CDKL5 (n = 2), KCNQ2 (n = 2), SCN1A (n = 2), SYNGAP1 (n = 2),
GNAO1 (n = 2), KCNT1 (n = 2), BRAT1, WWOX, ZEB2, CHD2, PRICKLE2, COL4A1, DNM1, SCN8A, MECP2, SLC9A6 (n = 1). The
other 3 patients had pathogenic CNVs (2 duplications and 1 deletion) with varying sizes (from 2.5 Mb to 12 Mb). The
overall diagnostic yield was 37.8% after following our step-by-step approach for clinical consensus.
Conclusions: NGS is a useful diagnostic tool with great utility for patients with EOE. Diagnostic yields can be
maximized with a standardized and team-based approach.
Keywords: Diagnostic yield, Early-onset epilepsy, Next-generation sequencing
Background
Early-onset epilepsy (EOE) in infancy or early childhood
is often a devastating form of epilepsy that is associated
with severe cognitive impairment. Etiologies remain
unidentified despite comprehensive structural,
metabolic, immunologic, infection, and genetic investi-
gations due to their heterogeneity [1]. Recently, several
studies demonstrated the usefulness of targeted next-
generation sequencing (NGS) for diagnosing EOE using
a genetic approach [2–6]. Previous studies have reported
increased diagnostic yields with NGS panels compared
to those obtained with other genetic tests [2, 7]. NGS
strategies have revolutionized epilepsy genomic research
by increasing the detection of de novo variants using tar-
geted sequencing and whole-exome sequencing (WES).
Nevertheless, clinical implications of diagnostic NGS
panel for EOE are currently limited. Previous studies
focused on identifying the efficacy of NGS in large,
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multicenter patient cohorts. Limited clinical descriptions
of patients were provided. Clinical questions regarding
the identification of patients who are most likely to show
positive genetic results, and strategies to increase the
diagnostic yields of NGS panel still remain to be
explored.
Here, we used a customized NGS panel to clinically
and genetically investigate a highly selected group of pa-
tients who developed EOE in infancy or early childhood
(≤3 years of age). All analytical steps were performed
within our center according to a systematized diagnostic
pipeline. Our goal was to optimize the clinical use of
NGS panel for EOE by finding the most important
analytical step that determines the diagnosis rate and
identifying patients who are most likely to show genetic
abnormalities.
Methods
Patients and clinical information
A total of 74 unrelated pediatric patients with EOE with-
out a known cause were recruited from the epilepsy
clinic in Severance Children’s Hospital from March 2015
to May 2016. As a nationwide referral center for EOE,
patient population generally includes severe epilepsy pa-
tients with unknown causes. All patients met the follo-
wing criteria: (1) seizure onset before the age of 3 years;
(2) multiple epileptiform discharges with severely disor-
ganized background activity on electroencephalography
(EEG); (3) diagnosed with drug-resistant epilepsy and
progressive developmental delay or with a known epilep-
tic encephalopathy syndrome; (4) no structural lesion
detected with brain magnetic resonance imaging (MRI);
(5) no metabolic abnormalities; (6) no abnormalities de-
tected with previous genetic tests; and (7) offspring of
asymptomatic Korean parents. For the diagnosis of
specific epilepsy syndrome, patients were classified
according to the 2010 International League Against
Epilepsy classification [8] and previous diagnostic
criteria.
All EEGs were reviewed by one of four pediatric
epileptologists (S.H.K, H.K, J.S.L, and H.D.K). All
EEG recordings were obtained according to the 10–
20 international system, using a 21-channel digital
EEG system (Xltek, Natus Medical Incorporated, San
Carlos, CA, USA). Data were recorded using a sam-
pling rate of 200 Hz with filter settings of 1–70 Hz.
Brain MRI was performed according to standard epi-
lepsy protocols, including oblique coronal view on
T2-weighted and fluid-attenuated inversion recovery
at 1.5−3.0 Tesla. Investigations for metabolic disorders
included plasma amino acid analysis, urine organic
acid analysis, homocysteine level, acylcarnitine profile
(total and free carnitine levels), blood gas analysis,
and serum lactate, pyruvate, and ammonia. Previous
genetic tests in each patient varied but usually
included chromosomal analysis, Sanger sequencing for
specific genes such as MECP2, and multiplex ligation-
dependent probe amplification (MLPA) using the
SALSA MLPA P245 Microdeletion Syndrome kit
(MRC Holland, Amsterdam, The Netherlands), which
were mainly performed before referral from various
other hospital to Severance Children’s Hospital.
For clinical analysis, previous seizure history was
reviewed in detail for the age of seizure onset, seizure
types, history of neonatal seizures, history of status
epilepticus, and febrile seizures. Information regarding
admission to the neonatal intensive care unit (NICU),
developmental state, and premature deaths were col-
lected. This study was approved by the Institutional
Review Board of Severance Hospital (IRB 4–2016-
0080). Informed consent was obtained from patients
or their parents.
Targeted gene sequencing using NGS panel
For the customized NGS panel, we selected 172 candidate
genes implicated in EOE based on an extensive literature
review and the Online Mendelian Inheritance in Man
(OMIM) database (http://www.ncbi.nlm.nih.gov/omim)
(listed in online Additional file 1: Table S1). These genes
include genes related to not only EOE, but also epilepsies
of inborn errors of metabolism and conditions that are in-
dications or contraindications of the ketogenic diet.
Genomic DNAs were extracted from leukocytes of
whole blood samples using the QIAamp Blood DNA
mini kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. Intact DNA was quantified
and adjusted to a concentration of 5 ng/μL using a
Qubit 2.0 Fluorometer (Invitrogen, Waltham, MA, USA)
and the Qubit dsDNA HS assay kit (Invitrogen). Precap-
ture libraries were constructed according to the manu-
facturer’s sample preparation protocol. Each patient’s
genomic DNA was fragmented to a median size of 300
base pair (bp). The DNA fragments were end-repaired,
phosphorylated, and adenylated on the 3′ ends. The
index adaptors were ligated to the repaired ends, DNA
fragments were amplified, and fragments of 200−500 bp
were isolated. Pooled libraries were sequenced using a
MiSeq sequencer (Illumina, San Diego, CA, USA) and
the MiSeq Reagent Kit v2 (300 cycles).
NGS data analysis
Data analysis was performed primarily through our
custom pipeline. Briefly, raw sequence data were
mapped to GRCh37 (hg19) using the Burrows-Wheeler
Aligner algorithm, followed by removal of duplicate
reads, realignment of insertions and deletions, base qual-
ity recalibration, and variant calling using the Genome
Analysis Toolkit (GATK). Small nucleotide variants
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called by GATK were further crosschecked with
BaseStudio software (Illumina). Every variant that was
suspected to be pathogenic, likely pathogenic, or variant
of unknown significance (VUS) was confirmed by visual
inspection of the bam file using Integrated Genomics
Viewer version 2.3 (IGV; Broad Institute, Cambridge,
MA, USA). Quality metrics were calculated for each
sample using the FastQC software and TEQC package.
Split-read-based detection of large insertions and
deletions was conducted using the Pindel and Manta
algorithms, and both results were finally crosschecked.
Read-depth-based detection of structural rearrange-
ments was conducted using the ExomeDepth soft-
ware. Chromosomal copy number variations (CNVs)
detected by ExomeDepth were further crosschecked
using our custom pipeline; this retrieved base-level
depth-of-coverage for each bam file using SAMtools
software and normalized the depths against those of
other samples in the same batch. We performed off-
target analysis of chromosomal copy number alter-
ations using the CopywriteR software.
The following databases were used for variant annota-
tion: OMIM, Human Gene Mutation Database (HGMD),
ClinVar, dbSNP, 1000 Genome, Exome Aggregation
Consortium (ExAC), Exome Sequencing Project, and
Korean Reference Genome Database (KRGDB). The
pathogenicity of missense variants was predicted using
five in silico prediction algorithms, including Sorting
Tolerant from Intolerant (SIFT), Polymorphism
Phenotyping v2 (PolyPhen-2), MutationTaster, Mutatio-
nAssessor, and Functional Analysis through Hidden
Markov Models (FATHMM) implemented in dbNSFP
version 3.0a. Effects on splicing were predicted using the
SPIDEX version 1.0 and dbscSNV version 1.1.
Annotation and interpretation of variants
Identified variants were described according to nomen-
clature recommendations of the Human Genome
Variation Society (http://www.hgvs.org/mutnomen). The
interpretation of variants followed the 5-tier classifica-
tion system recommended by the American College of
Medical Genetics and Genomics and the Association for
Molecular Pathology (ACMG/AMP) [9] using a step-by-
step approach (Fig. 1). Briefly, ACMG guideline defined
28 criteria that address evidence such as population
data, case-control analyses, functional data, computa-
tional predictions, allelic data, segregation studies, and
de novo observations. We evaluated all the possible
components in every patient by three-step analyses.
First, variants were filtered by their frequencies in
Fig. 1 Flow chart of our bioinformatics pipeline and variant classification results with interpretation
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population control databases, including ExAC (non-
TCGA dataset; frequencies were calculated according to
ethnic subgroups), ESP6500, 1000 Genomes Project, and
KRGDB. To maximize the diagnostic yield, variants with
a minor allele frequency (MAF) greater than 5% in any
of the population subgroups rather than conventional
1% criteria were classified as absolutely benign, whereas
those that were absent from the general population were
considered to have moderate evidence as pathogenic.
Second, literature and database searches for previous re-
ports and functional studies were performed using the
Alamut Visual 2.6 software (Interactive Biosoftware,
France) and HGMD professional database. When all in
silico analyses showed consistent predictions, the results
were regarded as evidence of benign or pathogenic
variants.
Phenotype review and consensus discussion
The last step involved genetic specialists or laboratory
physicians presenting a preliminary report to the pa-
tient’s attending physicians or pediatric epileptologists,
which listed all possible pathogenic variants, likely
pathogenic variants, and VUSs. The clinicians performed
an in-depth review of each patient’s phenotype and gave
an opinion from their point of view. Each case was fur-
ther reviewed and discussed in a monthly consensus
meeting that included the participation of all laboratory
personnel, bioinformaticians, geneticists, and clinicians.
When pathogenic or likely pathogenic variants were
consistent with the patient’s phenotype, final validation
using other confirmatory assays and a parental study
was planned. VUSs, especially missense variants, were
prioritized according to population frequency, ACMG
score, and the patient’s clinical phenotype. A parental
study was scheduled to detect de novo occurrence for
the candidate pathogenic, likely pathogenic, and VUS
variants in all available trios.
Confirmation using other methods
For small nucleotide variations, pathogenic and likely
pathogenic variants as well as VUSs needing parental
study were examined using Sanger sequencing on a 3730
DNA Analyzer with the BigDye Terminator v3.1 Cycle
Sequencing kit (Applied Biosystems, Foster City, CA,
USA). Sequencing data were aligned against appropriate
reference sequences and analyzed using the Sequencher
5.3 software (Gene Codes Corp., Ann Arbor, MI, USA).
Large exonic deletions and duplications were confirmed
using the MLPA kit (MRC Holland). Chromosomal copy
number alterations were confirmed using the Infinium
CytoSNP 850 K array (Illumina) and BlueFuse Multi soft-
ware (Illumina).
Statistical analysis
To compare clinical presentations among subgroups
according to epilepsy syndrome type or presence of de-
finitive genetic causes revealed by this study, Fisher’s
exact test, Chi-square test, and independent t-test were
utilized for comparisons of numerical and categorical
variables. Bonferroni correction was utilized for multiple
testing correction. Statistical analyses were computed
using the PASW statistics software (version 18.0, SPSS
Inc., Chicago, IL, USA). P-value <0.05 was considered
statistically significant.
Results
Demographics and clinical characteristics of patients
Demographics and clinical characteristics of all patients
are summarized in online Additional file 1: Table S2.
Mean age of seizure onset was 7.5 ± 7.8 months (stand-
ard deviation). Seizures started before the age of 1 year
in 85.1% of patients (63/74). Global developmental delay
was observed in 83.8% of patients (62/74). Among them,
17 (23.0%) patients could not make eye contact. Epilep-
tic spasms (70.3%) were the most common seizure type,
followed by generalized (33.8%) and focal (21.6%) seizure
types. Two patients had all three seizure types. Many pa-
tients had a remarkable perinatal history, which included
admission to the NICU in 23.0% of patients (17/74) and
a history of neonatal seizures in 15.0% of patients (11/
74). Six (8.1%) of the 74 patients had a history of status
epilepticus, and two (2.7%) had unexpected premature
deaths. The causes of death were pneumonia and sudden
infantile death syndrome. The epilepsy syndrome was di-
agnosed most commonly as infantile spasm (IS) (n = 51),
followed by Dravet syndrome (n = 2), malignant migrat-
ing focal seizures in infancy (MMFI) (n = 1), and Doose
syndrome (n = 1).
NGS run and quality metrics
Quality metrics of NGS runs for all patients are summa-
rized in online Additional file 1: Table S3. On average,
more than 8.7 million reads were sequenced per sample,
and approximately 8.0 million reads (93.5%) were
mapped on references. The average horizontal coverage,
which was interpreted as percentage of regions with
more than 20× coverage, was 99.8%.
Spectrum and statistics of pathogenic variants
Among the 28 patients with pathogenic or likely patho-
genic variants, 25 had single nucleotide variants (SNVs)
or nucleotide/exon deletions in 17 epilepsy-associated
genes (Table 1), and 3 had deletion or duplication of
large genomic segments (Table 2). Among the SNVs,
missense variants (n = 14) were the most common type,
followed by nonsense (n = 5), frameshift (n = 4), and
splice-site (n = 2) variants (Table 1). Two patients (P16
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and P17) were compound heterozygous for one SNV
and one exon-level deletion/duplication (Table 1, Fig. 2a).
The most commonly affected gene was STXBP1.
For CNVs, abnormalities were found in heterozygote
form for three different chromosomes in three patients
(Table 2, Fig. 2b). Two patients had seizure type of
epileptic spasms, whereas the seizure type of the other
patient was unknown. The affected segment sizes varied
from 2.5 to 12 Mb, and all CNVs were confirmed using
methylation-specific MLPA or array comparative gen-
omic hybridization. In patient P27, methylation-specific
MLPA confirmed deletion of maternal alleles in the
15q11.2 region, which contains SNRPN, UBE3A, and
GABRB3. The phenotype and distinctive EEG pattern of
patient P27 were compatible with Angelman syndrome,
which is prolonged runs of high amplitude rhythmic 2–
3 Hz activity predominantly over the frontal regions with
superimposed interictal epileptiform discharges and high
amplitude rhythmic 4–6 Hz activity prominent in the
occipital regions with spikes.
Overall, 16/51 (31.4%) patients with IS and 8/19
(42.1%) patients with unknown EOE could be genetically
diagnosed with our epilepsy NGS panel (online
Additional file 1: Table S4). The most common type of
mutation in IS was missense in STXBP1. Both patients
with Dravet syndrome harbored frameshift mutations in
SCN1A and one patient with Doose syndrome had a
CHD2 mutation.
Clinical factors associated with genetic abnormalities
When all patients with EOE were assessed together, we
did not find statistically significant differences in gender,
age of seizure onset, and history of neonatal seizures be-
tween the patients with sufficient genetic cause group
identified by NGS and the patients with negative results
group, except for history of febrile seizures (28.6% vs.
6.5%) (online Additional file 1: Table S5). However, when
only patients who had IS were assessed, severe clinical
outcomes were more prevalent in patients with genetic
cause than in patients without identified genetic cause.
Patients with an identified genetic cause were more
likely to never develop eye contact (50.0% vs. 17.1%,
P = 0.02) (Table 3). Also more patients had an earlier
seizure onset than in patients without a detected
pathogenic mutation, suggesting more severe epilepsy
in this group of patients with genetic causes (3.2 ±
3.0 months vs. 6.2 ± 4.4 months, P = 0.02).
Discussion
Using a customized NGS panel, more than one-third of
unknown EOEs could be diagnosed genetically. Given
the high diagnostic yield, NGS panel could be a powerful
diagnostic tool for clinical practices with EOE patients.
We developed a diagnostic process that pediatric epilep-
tologists and bioinformaticians can easily implement in a
clinical setting. Furthermore, we provide a simplified
flowchart that other epilepsy centers can follow by
showing benefits acquired at each step sequentially. All
analytical steps were carefully controlled, and diagnostic
rates at all stages were reviewed.
In this study, more than 170 genes were examined
to include as many genes as possible in order not to
underestimate the genetic contribution to epilepsy. As
anticipated, a few well-known genes accounted for the
majority of observed abnormalities. Single-gene muta-
tions accounted for 89.2% of all abnormalities de-
tected; these included 16 mutations (57.1%) in major
affected genes in our study (STXBP1, CDKL5,
KCNQ2, SCN1A, KCNT1, SYNGAP1, MECP2, and
GNAO1) and 9 mutations (32.1%) in various genes
(BRAT1, WWOX, ZEB2, CHD2, PRICKLE2, COL4A1,
DNM1, SCN8A, and SLC9A6). Although PRICKLE2 is
controversial to be defined as epilepsy-associated gene
based on previous studies, our case might serve as an
Table 2 Results of mutation analysis in 3 patients with pathogenic or likely pathogenic copy number variations
Patient Affected
region
Duplication/
Deletion
Size Major genes
involved in
the region
Additional
study
Result of the
additional study
Zygosity Suspected
syndrome
Phenotypic correlation
P26 14q11.2-
q12
Duplication 12 Mb FOXG1,
CHD8,
SUPT16H
array CGH arr 14q11.2(20,528,
528–32,297,926)×3
Heterozygosity Not availablea Early onset of infantile
spasms,Developmental
delay
P27 15q11.2 Deletion 3.5 Mb UBE3A,
GABRB3,
SNRPN
MLPA Deletion of
maternal allele
Heterozygosity Angelman
syndrome
Distinctive electro-
encephalography
patternc
P28 19p13.3 Duplication 2.5 Mb Not specific
epilepsy-
associated
genes
array CGH arr 19p13.3(3,462,
574–6,583,781)×3
Heterozygosity 19p13.3
microduplication
syndromeb
Distinctive facial
dysmorphism
a No definitive syndrome was suggested until the two most recent literatures [22, 23]
b New microduplication syndrome was suggested by Carmen et al. [24]
c High amplitude rhythmic 4–6 Hz activity, prominent in the occipital or frontal regions with spikes
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Fig. 2 (See legend on next page.)
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additional evidence for pathogenicity. Overall, 90.2%
(156) of the 172 genes in our panel showed no abnor-
malities. These results suggest that the currently
recognized causative genes of EOE can only account
for a very small fraction of the total causes of EOE,
and more genes can cause EOE than have been pre-
viously reported.
Our results are consistent with those of previous
studies [2, 7]. A recent Chinese study used an NGS
panel for EOE that included 17 genes, and successfully
diagnosed 32% (56/175) of patients [10]. A recent
Japanese study examined 35 genes and diagnosed 23%
(12/53) of patients [11]. Except for a few commonly mu-
tated genes, most pathogenic variants in other genes
with minor frequency seem to be rare causes of EOE.
The diagnostic yield of NGS panel appeared to be deter-
mined by the number of commonly mutated genes in-
cluded in the panel rather than the total number of
genes in the panel [12]. This result might indicate that
specific genes which have been repeatedly reported by
multiple centers in multiple patients who share similar
clinical phenotypes including epilepsy deserve more cau-
tious and detailed analysis than other genes. Clinical use
of NGS panel for EOE will be maximized when the inci-
dence of all causative genes is determined and
considered, rather than blindly increasing the number of
genes in a panel with a hope to proportionally increase
the diagnostic rate.
Patient inclusion criteria play a critical role in deter-
mining the diagnostic rate of NGS panel. The diagnostic
rate increases when the study includes only narrowly
classified patients with severe clinical phenotypes. In our
EOE study, patients with febrile seizures and poor eye
contact were more likely to exhibit genetic abnormal-
ities. This phenomenon was more clearly demonstrated
in the IS patient subgroup, and patients were more likely
to exhibit genetic abnormalities if they had early onset
epileptic spasms or poor eye contact (P < 0.05). These re-
sults suggest that patients with unexplained IS are more
likely to exhibit abnormalities in the NGS panel if they
experience seizures at younger ages and have more
phenotypic traits, such as absence of eye contact.
Although intractable epilepsy is a condition that can
occur at any age, it occurs most frequently in infancy
and early childhood. In this study, we included only
patients who met the following criteria: (1) seizures
before 3 years of age and (2) progressive refractory
EOE of unknown origin or well-known refractory
epilepsy syndrome. We believe that our study was
performed with the strict inclusion criteria, including
(See figure on previous page.)
Fig. 2 Profiles of mutations detected in our study. a Exonic deletions and duplications detected by relative-depth comparisons. a-1 Heterozygous
deletion involving exons 2−3 in the BRAT1 gene of patient 16 (P16), (a-2) heterozygous duplication involving exons 6−8 in the WWOX gene in
patient 17 (P17). b Examples of chromosomal copy number alterations detected by off-target analysis of targeted next-generation sequencing
results. b-1 Heterozygous deletion of the 15q11.2 region (downward arrow) observed in patient 27. b-2 Heterozygous duplication of the 19p13.3
region (upward arrow) observed in patient 28
Table 3 Clinical and demographic information of the patients with infantile spasm
Total number Group 1 (Patients with positive
genetic cause, % within group 1)
Group 2 (Patients without positive
genetic cause, % within group 2)
P-value
Number of subjects 51 16 35
Female 23 10 (62.5) 13 (37.1) 0.09
Seizure onset (months) 1.00
0 < n ≤ 12 months 49 16 (100) 33 (94.3)
12 months < n ≤ 24 months 2 0 2 (5.7)
24 months < n ≤ 36 months 0 0 0
mean age (± standard deviation) 3.2 (± 3.0) 6.2 (± 4.4) 0.02
Global developmental delay 41 14 (87.5) 27 (77.1) 0.47
Absence of eye contact 14 8 (50.0) 6 (17.1) 0.02
Neonatal seizures 9 5 (31.3) 4 (11.4) 0.12
Febrile seizures 2 2 (12.5) 0 0.09
Status epilepticus 1 0 1 (2.9) 1.00
Premature death 2 1 (6.3) 1 (2.9) 0.53
NICU stay 20 7 (43.8) 8 (22.9) 0.19
Rim et al. BMC Medical Genomics  (2018) 11:6 Page 8 of 10
age limits. In previous studies, the diagnostic rate of
NGS panel tended to negatively correlate with age
limits. The diagnostic rates increased to 32% when
only patients under 6 months of age were included
[10], and declined to 12% when all patients under
18 years of age were included [13]. However, it is
possible that selection bias of patients with severe
phenotypes might have caused relatively high diagno-
tic yield in this study.
Many studies have proved the clinical usefulness of
NGS panel, and more epilepsy centers will use NGS
panel for the management of EOE. An objective and
standardized interpretation of data is critical for aca-
demic communication and validation [14]. Here, we
show the importance of analyzing the genomic data
systematically using a standardized approach. We
found that accurate interpretation of gene abnorma-
lities requires the following three crucial components:
(1) population data and database review; (2) computa-
tional data, allelic data, and literature review; and (3)
detailed clinical review, family study, and consensus
discussions. Our analysis process presented the diag-
nostic yield of the NGS panel to be 37.8%. It should
also be emphasized that consensus discussions can
occur only when bioinformaticians, geneticists, and
clinical neurologists closely communicate. We con-
ducted multi-disciplinary team meetings every month,
supported by frequent online and offline communica-
tions. Our study emphasizes the importance of collab-
orative work for correct interpretation of NGS results.
The benefits of team interpretations of genomic data
in rare diseases have been previously emphasized [15].
In this study, we demonstrate that team interpretation
can be particularly beneficial for managing patients
with EOE whose known genes and genetic inheritance
patterns are diverse.
In our study, exonic and chromosomal CNVs were
identified in 2.7% (2/74) and 4.1% (3/74) of patients,
respectively. The importance of CNVs in epilepsy
has been confirmed in previous studies [16–18].
With the rapid evolution of NGS technologies and
algorithms, CNV detection using NGS could replace
traditional methods. Exonic CNVs can be detected
using relative depth comparisons, and whole
chromosomal CNVs can be detected using off-target
analysis. All identified CNVs were confirmed by
MLPA or chromosomal microarrays, as well as
phenotype comparison with patients of similar af-
fected regions such as distinctive facial dysmorphism
(P28 in Table 2). We also concluded that off-target
analysis could be an effective and practical way to
detect chromosomal CNVs, and targeted NGS testing
may serve as a candidate first-line genomic test to
replace chromosomal microarrays.
Unfortunately, we failed to identify causal mutations
for approximately two-thirds of patients. Unknown
genes may be causative factors in these patients [19, 20].
The fact that several NGS or WES studies have reported
similar percentages of negative results [5, 10, 21] indi-
cate that other genetic mechanisms including epigenetics
and somatic mutation may play a role.
Conclusions
In conclusion, this study demonstrated that the targeted
NGS panel has excellent diagnostic performance and
great utility for managing patients with EOE. Accurate
and appropriate interpretation with extensive CNV de-
tection strategies increased the diagnostic yield of tar-
geted NGS.
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